Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective study of intravitreal ranibizumab for exudative age-related macular degeneration in Japanese patients
jRCTs021180003Completed
- Sponsor
- Novartis
- Start
- Aug 2017
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of ranibizumab in age-related macular degeneration (AMD), sponsored by Novartis. Primary endpoint: Mean change in best-corrected visual acuity at Month 24 compared with baseline. Started Aug 2017; status: completed.
02
Drugs
ranibizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on jRCTs021180003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021180003.